BIOVENTUS INC - A
BVSNASDAQTrading Snapshot
- Day Range
- $210.35 β $216.40
- 52-Week Range
- $6.26 β $15.89
- Volume
- $2.81B
- Avg Volume
- $1.90B
- Shares Outstanding
- 67.8M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $568M
- Last Q Revenue
- $153M
- P/E Ratio
- 21.6
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.78
- Dividend Yield
- β
- Dilution (1yr)
- +5.3%
Why Investors Own BVS
- βHigh-growth profile β revenue up +17.7% YoY with expanding US Equity exposure.
- βHealthy economics β 51% gross margin and 26% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIOVENTUS INC - A
BVSAbout BIOVENTUS INC - A
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The companyβs product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The companyβs restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
BIOVENTUS INC - A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BVS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BIOVENTUS INC - A announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.